Neuralink Expands Human Trials to 21 Participants as Musk Announces Next-Generation Brain Implant
核心洞察
Neuralink (搜索) has expanded its human clinical trials to 21 participants worldwide, nearly doubling from the 12 reported in September 2024.
Elon Musk announced that a next-generation brain implant with three times the current capabilities is expected to be ready later this year.
The brain-computer interface (搜索) technology enables paralyzed patients to control computers, digital devices, and robotic arms using only their thoughts.
Elon Musk's brain-computer interface (搜索) company Neuralink (搜索) has significantly expanded its human clinical trials, now enrolling 21 participants worldwide as the company prepares to launch a next-generation implant with enhanced capabilities later this year.
The expansion represents substantial growth from the 12 participants reported in September 2024, demonstrating accelerated progress in the company's efforts to develop brain-computer interface (搜索) technology for individuals with paralysis (搜索) and spinal cord injuries (搜索).
Clinical Trial Progress and Capabilities
Current trial participants have successfully demonstrated the technology's potential across multiple applications. According to the company, patients are using Neuralink (搜索) devices to play video games, browse the internet, post on social media, and navigate cursors on laptops using only their thoughts.
"Our brain-computer interface (搜索) translates neural signals into actions. In our clinical trials, people are using Neuralink (搜索) devices to control computers and robotic arms with their thoughts," the company states on its official website.
The implants are primarily designed to assist people with paralysis (搜索) or spinal cord injuries (搜索) by bridging communication from the cortex past damaged areas in the neck or spine. Musk expressed confidence in the technology's potential, stating, "I am confident at this point that restoring full body functionality is possible with Neuralink (搜索)."
Next-Generation Technology Development
Musk announced that Neuralink (搜索)'s next-generation cybernetic implant, offering three times the capability of the current device, is expected to be ready later this year. The company emphasized that expanding clinical trials aims to "better understand these variations and improve both our hardware and the overall procedure for every participant."
The current device includes a chip that replaces a small piece of bone and connects to the brain via thin, threaded electrodes. According to the company, this technology is designed to "restore autonomy to those with unmet medical needs, unlocking new dimensions of human potential."
Vision Restoration Breakthrough
Beyond motor function restoration, Neuralink (搜索) is advancing toward vision restoration through its Blindsight device. The technology received "breakthrough device" designation from the US Food and Drug Administration in September, marking a significant regulatory milestone.
Musk indicated that Blindsight will help people who have lost both their eyes and claimed the device can potentially assist even those blind from birth. The approach involves starting with low-resolution sight and improving capabilities over time.
Regulatory and Development Timeline
Neuralink (搜索) began human trials in 2024 after addressing safety concerns initially raised by the FDA in 2022. The motor cortex (搜索) technology was first announced by Musk in 2022, with human trials commencing in the same year.
The company's expansion from 12 to 21 participants represents a 75% increase in trial enrollment, indicating accelerated recruitment and potentially broader eligibility criteria as the technology demonstrates safety and efficacy in early participants.